Featured Research

from universities, journals, and other organizations

Study Shows Calcitonin-Salmon Nasal Spray Helps Prevent New Spinal Fractures In Women With Existing Osteoporosis

Date:
September 16, 1998
Source:
University Of Washington
Summary:
A recently completed study shows that calcitonin-salmon nasal spray reduced by 36 percent the incidence of new spinal fractures in postmenopausal women with osteoporosis.

A recently completed study shows that calcitonin-salmon nasal spray reduced by 36 percent the incidence of new spinal fractures in postmenopausal women with osteoporosis.

Dr. Charles Chesnut, professor of radiology and medicine at the University of Washington in Seattle, presented results of the study at the European Congress on Osteoporosis in Berlin on Sept. 14.

Calcitonin-salmon is currently indicated for treatment of osteoporosis in women who are more than five years past menopause and for whom estrogen replacement therapy is not an option.

More than 1,200 women who had already experienced at least one spinal fracture took part in the five-year trial, called the Prevent Recurrence of Osteoporotic Fractures (PROOF) Study, conducted at 42 sites in the United States and five sites in the United Kingdom. The study was funded by Novartis Pharmaceuticals Corporation, which markets the drug in the U.S. as Miacalcin Nasal Spray.

Women taking calcitonin-salmon nasal spray (one spray of 200 IUs per day) experienced 36 percent fewer new spinal fractures than those taking placebo. All participants took supplemental calcium and vitamin D. There was no increase in side effects overall compared with women receiving placebo.

"The study results should provide encouragement to the millions of women who have suffered from the debilitating effects of a spinal fracture," said Chesnut, principal investigator on the study. "The data confirm the ability of a medicine known to be safe to reduce spinal fractures."

Based on the study results, Novartis filed a supplemental new-drug application with the U.S. Food and Drug Administration in July 1998, for use of calcitonin-salmon nasal spray for prevention of spinal fractures.

Spinal fractures (compressed vertebrae) are the most common complication of osteoporosis. Of the 1.5 million osteoporotic fractures that occur annually in the U.S., 700,000 occur in the spine, according to the National Osteoporosis Foundation.

Spinal fractures result in such irreversible changes as loss of height and stooped posture. However, fractures of the spine and a shrinking frame are not inevitable consequences of aging.

Clinical trials have shown that side effects from calcitonin-salmon are comparable to placebo. Most commonly reported side effects are nasal irritation such as runny nose, crusting and nosebleed, back and/or joint pain, and headache. Because calcitonin is a protein, the possibility of a systemic allergic reaction exists.


Story Source:

The above story is based on materials provided by University Of Washington. Note: Materials may be edited for content and length.


Cite This Page:

University Of Washington. "Study Shows Calcitonin-Salmon Nasal Spray Helps Prevent New Spinal Fractures In Women With Existing Osteoporosis." ScienceDaily. ScienceDaily, 16 September 1998. <www.sciencedaily.com/releases/1998/09/980916073652.htm>.
University Of Washington. (1998, September 16). Study Shows Calcitonin-Salmon Nasal Spray Helps Prevent New Spinal Fractures In Women With Existing Osteoporosis. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/1998/09/980916073652.htm
University Of Washington. "Study Shows Calcitonin-Salmon Nasal Spray Helps Prevent New Spinal Fractures In Women With Existing Osteoporosis." ScienceDaily. www.sciencedaily.com/releases/1998/09/980916073652.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins